#United States #Waltham #Dash Bio #bioanalysis

Dash Bio Expands Operations in Waltham, MA

On February 3, 2026, Dash Bio, a pioneering contract research organization (CRO) specializing in bioanalysis, announced its relocation to a modern 24,000 square foot facility in Waltham, Massachusetts. This new lab is designed to significantly accelerate the process of drug development, allowing the company to provide results in a matter of days rather than the traditional two to four months typically seen in the industry.

This expansion marks a pivotal moment for Dash Bio, representing a more than five-fold increase in capacity. The new facility is GLP-compliant, ensuring that all operations adhere to Good Laboratory Practice standards. This is crucial for biotech companies that depend on regulatory compliance for their projects. As of now, the lab is fully operational and ready to accept new projects immediately, eliminating delays often associated with lab transitions.

CEO Dave Johnson, who co-founded the company after a notable tenure at Moderna as Chief Data and AI Officer, shared his excitement about the new facility. He stated, “This facility gives us the capacity to serve more biotech companies who are tired of waiting months for data that should take days. We built this company because we know speed matters in drug development, and this expansion lets us deliver faster bioanalysis at scale.”

Key Features of the New Facility

• - Expanded capacity: The new Waltham facility is purpose-built to manage increased demands for bioanalysis services, enhancing the company's ability to assist more biotech clients.
• - Tech-enabled speed: Dash Bio is reducing turnaround times from the industry standard of four to six weeks to just three days. This efficiency is vital for companies in the fast-paced sector of drug discovery.
• - Automated workflows: By leveraging automation, the facility minimizes traditional manual bottlenecks. This shift allows for consistent quality and output, which is essential for meeting the rigorous demands of drug development.
• - Enhanced sample storage: The facility includes advanced infrastructure for long-term sample storage, accommodating the long-term needs of growing biotech programs.

The timing of this expansion is particularly relevant as Dash Bio continues to gain traction among biotech companies who have grown frustrated with the slow response times typical of older CROs. The company was founded in 2024 by a group of industry veterans and has successfully raised $17.5 million in funding to drive innovation in bioanalysis through automation.

About Dash Bio

Dash Bio is dedicated to reshaping the landscape of bioanalysis by providing results in days through a commitment to automation and transparent pricing. Founded by leaders in the biotech sector, including CEO Dave Johnson, COO Ander Tallett, and CSO Ely Porter, the company aims to eliminate the obstacles that hinder swift drug development. Their services cater to biotech companies across diverse therapeutic areas and feature clear pricing structures with no hidden fees.

In summary, Dash Bio's new facility is not just an expansion; it's a bold step forward in revolutionizing how bioanalysis is conducted in the biotech industry. With their enhanced capabilities, they are poised to set new standards for efficiency and reliability in drug development, ultimately benefiting patient outcomes when novel therapies are brought to market more swiftly.